natgillin/translations-raw huggingface dataset:
Blood alkaline phosphatase increased
Povišana gama-glutamiltransferaza Povišana alkalna fosfataza v krvi
Keep this medicine out of the sight and reach of children.
Zdravilo hranite na mestu, ki ga otroci ne vidijo in ne dosežejo.
Vertigo Tinnitus
Angina pektoris
After a single 1340 microgram dose, mean Cmax was 10.2 to 25.2 ng/mL across healthy subject and patient studies.
V preskušanjih pri zdravih prostovoljcih in pri bolnikih je bila povprečna Cmax po enkratnem odmerku 1340 mikrogramov 10,2 do 25,2 ng/ml.
Each capsule contains tivozanib hydrochloride monohydrate equivalent to 890 microgram of tivozanib.
Ena trda kapsula vsebuje tivozanibijev klorid monohidrat v količini, ki ustreza 890 mikrogramom tivozaniba.
Talk to your doctor, pharmacist or nurse before taking Fotivda:
Opozorila in previdnostni ukrepi Preden začnete jemati zdravilo Fotivda, se pogovorite z zdravnikom, farmacevtom ali medicinsko sestro:
Alopecia Rash24 Acne25
Pruritus23 Alopecija Izpuščaj24 Akne25 Suha koža
METHOD AND ROUTE(S) OF ADMINISTRATION
POSTOPEK IN POT(I) UPORABE ZDRAVILA Oralna uporaba.
Arthralgia Myalgia Musculoskeletal chest pain
Mišično-skeletna bolečina v prsnem košu
Tabulated summary of adverse reactions
Povzetek neželenih učinkov, prikazan v obliki preglednice
Coronary artery insufficiency
Pljučni edem Koronarna insufienca
How to store Fotivda
Shranjevanje zdravila Fotivda
Fotivda 890 microgram
PODATKI V BRAILLOVI PISAVI Fotivda 890 mikrogramov
Hard capsule with dark blue opaque cap and bright yellow opaque body, printed with yellow ink “TIVZ” on the cap and with dark blue ink “LD” on the body.
Trda kapsula s temnomodrim neprozornim pokrovčkom in svetlorumenim neprozornim telesom, z rumenim napisom “TIVZ” na pokrovčku in svetlorumenim napisom “LD” na telesu kapsule.
Chest pain28 Chills29 Pyrexia Peripheral oedema
Bolečina v prsnem košu28 Mrazenje29
Skin exfoliation Erythema22 Pruritus23
Pankreatitis17 Disfagija18
- Printing ink, blue: shellac, propylene glycol, strong ammonia solution, indigo carmine aluminium lake (E132).
- Tiskarska barva, rumena: šelak, propilenglikol, koncentrirana raztopina amoniaka, titanov dioksid (E171), tartrazin (E102).
Fotivda 1340 microgram
PODATKI V BRAILLOVI PISAVI Fotivda 1340 mikrogramov
Magnetic Resonance Imaging is necessary to confirm the diagnosis of PRES. Tivozanib must be discontinued in patients developing signs or symptoms of PRES.
Pri bolnikih, ki razvijejo znake ali simptome PRES je treba zdravljenje s tivozanibom prekiniti.
Always take this medicine exactly as your doctor has told you.
Kako jemati zdravilo Fotivda Pri jemanju tega zdravila natančno upoštevajte navodila zdravnika.
Strong ammonia solution Indigo carmine aluminium lake (E132)
šelak propilenglikol koncentrirana raztopina amoniaka indigotin (E132)
• Unable to sleep.
• Nespečnost.
Ear and labyrinth disorders
vključno z motnjami labirinta
EU/1/17/1215/002
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/17/1215/002
Duodenal ulcer
Pireksja Periferni edem
Proteinuria has been reported in clinical studies with tivozanib (see section 4.8).
Pri kliničnem preskušanju tivozaniba so poročali o proteinuriji (glejte poglavje 4.8).
• Headache
• Driska.
Hard capsule with bright yellow opaque cap and bright yellow opaque body, printed with dark blue ink “TIVZ” on the cap and with dark blue ink “SD” on the body.
Trda kapsula s svetlorumenim neprozornim pokrovčkom in svetlorumenim neprozornim telesom, s temnomodrim napisom “TIVZ” na pokrovčku in temnomodrim napisom “SD” na telesu kapsule.
EU/1/17/1215/001
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/17/1215/001
ALT increased / AST increased21
Povišana ALT/povišana
The most frequent adverse reactions leading to tivozanib dose reduction/ interruption were hypertension (4.7%), diarrhoea (3.1%), fatigue
Najpogostejši neželeni učinki, ki je vodili do zmanjšanja odmerka ali prekinitve zdravljenja s tivozanibom, so bili hipertenzija
Renal impairment
Astenija Utrujenost
In case you experience severe side effects, your doctor may decide to interrupt Fotivda therapy and/or lower the dose to:
Če se vam pojavijo hudi neželeni učinki, se lahko zdravnik odloči prekiniti zdravljenje z zdravilom
EXPIRY DATE
Navzea Diareja
Dizziness Dysgeusia3
Suha usta Flatulenca
Each hard capsule contains tivozanib hydrochloride monohydrate equivalent to 1340 microgram tivozanib.
Fotivda 1340 mikrogramov trde kapsule Ena trda kapsula vsebuje tivozanibijev klorid monohidrat v količini, ki ustreza 1340 mikrogramom tivozaniba.
What measures are being taken to ensure the safe and effective use of Cresemba?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cresemba?
It must also not be used in patients with familial short QT syndrome, a heart rhythm problem.
Prav tako se ne sme uporabljati pri bolnikih s sindromom prirojenega kratkega intervala QT, tj. težavami s srčnim ritmom.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Cresemba's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cresemba večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Cresemba must not be used in patients who are taking any of the following:
Zdravilo Cresemba se ne sme uporabljati pri bolnikih, ki jemljejo karkoli od naslednjega:
The summary of the opinion of the Committee for Orphan Medicinal Products for Cresemba can be found on the Agency's website:
Povzetek mnenja Odbora za zdravila sirote o zdravilu Cresemba je na voljo na spletni strani agencije:
This is a summary of the European public assessment report (EPAR) for Cresemba.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cresemba.
Other information about Cresemba
Druge informacije o zdravilu Cresemba
What are the risks associated with Cresemba?
Kakšna tveganja so povezana z zdravilom Cresemba?
The most common side effects with Cresemba (seen in more than 10% of patient studied) were: abnormal liver tests, nausea, vomiting, difficulty breathing, abdominal pain, diarrhea, injection site reactions, headache, low blood potassium and skin rash.
Najpogostejši neželeni učinki zdravila Cresemba (opaženi pri manj kot 10 % proučevanih bolnikov) so bili: nenormalni izvidi preiskav jeter, slabost, bruhanje, oteženo dihanje, bolečine v trebuhu, driska, reakcije na mestu injiciranja, glavobol, nizke ravni kalija v krvi in kožni izpuščaj.
It works by disrupting the formation of ergosterol, an important component of fungal cell membranes.
Deluje tako, da ovira tvorbo ergosterola, ki je pomembna sestavina celičnih membran glivic.
What is Cresemba and what is it used for?
Kaj je zdravilo Cresemba in za kaj se uporablja?
The full EPAR and risk management plan summary for Cresemba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Cresemba sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A risk management plan has been developed to ensure that Cresemba is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Cresemba je bil pripravljen načrt obvladovanja tveganj.
What benefits of Cresemba have been shown in studies?
Kakšne koristi je zdravilo Cresemba izkazalo v študijah?
Why is Cresemba approved?
Zakaj je bilo zdravilo Cresemba odobreno?
In addition, Cresemba has the advantage that it can be used in patients with reduced kidney function.
Poleg tega ima zdravilo Cresemba to prednost, da se lahko uporablja pri bolnikih z zmanjšanim delovanjem ledvic.
It is not intended to provide practical advice on how to use Cresemba.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Studies show that survival following treatment with Cresemba is similar to that seen with other treatments.
Študije so pokazale, da je bilo preživetje po zdravljenju z zdravilom Cresemba podobno kot po zdravljenju z drugimi zdravili.
Invasive aspergillosis and mucormycosis are life-threatening infections associated with high mortality.
Invazivna aspergiloza in mukormikoza sta smrtno nevarni okužbi, povezani z veliko umrljivostjo.
• ketoconazole (an antifungal)
• ketokonazol (antimikotik);
Without a functional cell membrane, the fungus is killed or prevented from spreading.
Brez delujoče celične membrane glivice odmrejo oziroma se ne morejo širiti.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cresemba, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Cresemba in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The dosage for the infusions and capsules are the same: 200 mg every 8 hours for the first 48 hours, followed by a 200-mg maintenance dose once a day.
Odmerjanje pri infundiranju in uporabi kapsul je enako: šest odmerkov po 200 mg vsakih osem ur v obdobju 48 ur, ki jim sledi vzdrževalni odmerek 200 mg enkrat na dan. Trajanje zdravljenja je odvisno od tega, kako se bolnik odzove na zdravljenje.
ema.europa.eu/Find medicine/Human medicines/Rare disease designation (mucormycosis)
ema.europa.eu/Find medicine/Human medicines/Rare disease designation (mukormikoza)
For more information about treatment with Cresemba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Cresemba preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
• high-dose ritonavir (an HIV medicine)
• visokoodmerni ritonavir (zdravilo proti virusu HIV);
ema.europa.eu/Find medicine/Human medicines/Rare disease designation (invasive aspergillosis)
ema.europa.eu/Find medicine/Human medicines/Rare disease designation (invazivna aspergiloza)
Although amphotericin B is the first line treatment for mucormycosis, there is a need for alternative treatments and Cresemba will benefit patients for whom amphotericin B is not appropriate.
Čeprav je zdravilo prve izbire za mukormikozo amfotericin B, obstaja potreba po alternativnih zdravilih, zato bo zdravilo Cresemba koristno za bolnike, za katere amfotericin B ni primeren.
For mucormycosis, Cresemba is used when amphotericin B is inappropriate.
Pri mukormikozi se zdravilo Cresemba uporablja, kadar uporaba amfotericina B ni primerna.
For practical information about using Cresemba, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Cresemba naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Cresemba is an antifungal medicine used to treat adults with either of two life-threatening fungal infections: invasive aspergillosis and mucormycosis.
Cresemba je zdravilo proti glivicam, ki se uporablja za zdravljenje odraslih z eno od dveh smrtno nevarnih glivičnih okužb: invazivno aspergilozo ali mukormikozo.
Regarding safety, Cresemba was relatively well tolerated.
Kar zadeva varnost, so bolniki zdravilo Cresemba na splošno dobro prenašali.
Because the number of patients with these diseases is low, they are considered ‘rare', and Cresemba was designated an ‘orphan medicine' (a medicine used in rare diseases) on 4 June 2014 (for mucormycosis) and 4 July 2014 (for aspergillosis).
Ker je bolnikov s tema boleznima malo, veljata bolezni za redki, zato je bilo zdravilo Cresemba 4. junija 2014 (za mukormikozo) in 4. julija 2014 (za aspergilozo) določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
In a main study of 516 patients with invasive aspergillosis, the mortality rate at 42 days was similar in patients treated with Cresemba (19%) and those treated with another antifungal medicine voriconazole (20%).
V glavni študiji, v kateri je sodelovalo 516 bolnikov z invazivno aspergilozo, so po 42 dneh zabeležili podobno umrljivost pri bolnikih, zdravljenih z zdravilom Cresemba (19 %), in tistih, ki so jih zdravili z drugim zdravilom proti glivicam, vorikonazolom (20 %).
For the full list of all side effects reported with Cresemba, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Cresemba, glejte navodilo za uporabo.
• certain medicines that enhance the breakdown of isavuconazole in the body (strong inducers of
• določena zdravila, ki pospešujejo razgradnjo izavukonazola v telesu (močni induktorji CYP3A4/5;
It is possible to switch between the infusion and the oral capsule if needed.
Po potrebi je mogoče z infundiranja preiti na peroralne kapsule in obratno.
Cresemba is available as a powder used to make a solution for infusion (drip) into a vein and as capsules to be taken by mouth.
Zdravilo Cresemba je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalno infuzijo) v veno in kapsul, ki se jemljejo peroralno.
In studies, Cresemba's effect was comparable to that of voriconazole in treating invasive aspergillosis.
V študijah je bil učinek zdravila Cresemba pri zdravljenju invazivne aspergiloze primerljiv z učinkom vorikonazola.
How is Cresemba used?
Kako se zdravilo Cresemba uporablja?
The active substance in Cresemba, isavuconazole, belongs to the ‘triazole' class of antifungal medicines.
Zdravilna učinkovina v zdravilu Cresemba, izavukonazol, spada v skupino zdravil proti glivicam, ki jih imenujemo „triazoli“.
Another study included 146 patients, among which 37 patients had mucormycosis and were treated with Cresemba; in patients with mucormycosis the mortality rate after 84 days was 43%, which is similar to rates seen in the published literature for standard treatments with amphotericin-B.
V drugi glavni študiji je sodelovalo 146 bolnikov z bodisi invazivno aspergilozo ali mukormikozo, med katerimi je bilo 37 bolnikov, ki so imeli mukormikozo in so prejemali zdravilo Cresemba - pri bolnikih z mukormikozo je umrljivost po 84 dneh znašala 43 %.
Cresemba contains the active substance isavuconazole.
Zdravilo Cresemba vsebuje zdravilno učinkovino izavukonazol.
How does Cresemba work?
Kako zdravilo Cresemba deluje?
This dose should be maintained for about 1 week.
Ta odmerek je treba vzdrževati približno 1 teden.
- if you are more than 3 months pregnant.
- če ste noseči dlje kot 3 mesece.
{Name and address} {tel} {fax} {e-mail}
{Ime in naslov} {tel} {fax} {e-mail}
Cough is more common in women and non-smokers.
Kašelj je pogostejši pri ženskah in nekadilcih.
2040 / Budaörs Hungary
2040 / Budaörs Madžarska
Children: Safety and efficacy in children have not been established.
Otroci: Varnost in učinkovitost pri otrocih nista ugotovljeni.
- Aldosterone antagonists.
- antagoniste aldosterona.
The long term efficacy of cilazapril (alone or in combination) has also been accepted in the majority of the EU countries.
Dolgoročno učinkovitost cilazaprila (dajanega samostojno ali v kombinaciji) so sprejeli tudi v večini držav EU.
- Sympathomimetics.
- simpatomimetike.
Germany: Dynorm
Nemčija: Dynorm
- if you are planning to have an operation (including dental surgery).
- če imate predvideno operacijo (vključno z zobozdravstvenimi posegi).
Taking this medicine - Take one tablet of Vascace each day.
Jemanje tega zdravila - Vsak dan vzemite eno tableto zdravila Vascace.
- Low numbers of all types of white blood cells.
- majhno število vseh vrst belih krvnih celic.
These patients also have a higher risk of angioedema.
Ti bolniki imajo tudi večje tveganje angioedema.
Netherlands: Vascase
Nizozemska: Vascase
Estrada Nacional 249-1 2720-413 / Amadora Portugal
Estrada Nacional 249-1 2720-413 / Amadora Portugalska
Belgium, Bulgaria, Czech Republic, Hungary, Luxembourg, Poland, Spain: Inhibace France: Justor
Belgija, Bolgarija, Češka, Madžarska, Luksemburg, Poljska, Španija:Inhibace Francija: Justor
QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients, see section 6.1.
KAKOVOSTNA IN KOLIČINSKA SESTAVA Za celoten seznam pomožnih snovi glejte poglavje 6.1.
- Any medicines used to treat high blood pressure.
- kakršnakoli zdravila za zdravljenje visokega krvnega tlaka.
This is more likely to happen when you first start treatment.
Njen pojav je verjetnejši, ko prvič začnete zdravljenje.
However this does not mean that the use of cilazapril would have to be automatically contraindicated in all types of renovascular hypertension.
Vendar to ne pomeni, da je uporaba cilazaprila samodejno kontraindicirana pri vseh vrstah renovaskularne hipertenzije.
Clinical / efficacy studies
Klinične študije/študije učinkovitosti
If you feel dizzy, do not drive or use any tools or machines.
Če ste omotični, ne upravljajte vozil ali strojev.
Frequency categories are as follows:
Kategorije pogostnosti so:
Austria: Inhibace "Roche"
Avstrija: Inhibace „Roche“
As this is a single study giving divergent results in this regard, the issue was not further questioned by the CHMP.
Ker je to posamezna študija, ki daje drugačne rezultate, CHMP o tej zadevi ni nadalje razpravljal.
Time of medication intake and meals
Čas zaužitja zdravila in obroki
The dose should always be taken at about the same time of day.
Odmerek je treba vedno vzeti ob približno istem času.
- Low blood pressure.
- nizek krvni tlak.
- Tricyclic antidepressants, antipsychotics.
- triciklične antidepresive, antipsihotike.
- Do not take a double dose (two doses at the same time) to make up for a forgotten dose.
- Ne vzemite dvojnega odmerka (dveh odmerkov hkrati), če ste pozabili vzeti prejšnji odmerek.
11 avenue Dubonnet 92 400 Courbevoie France
11 avenue Dubonnet 92 400 Courbevoie Francija
Cilazapril is efficiently absorbed and rapidly converted to the active form, cilazaprilat.
Cilazapril se učinkovito absorbira in se hitro spremeni v aktivno obliko, cilazaprilat.
Thereafter, the maintenance dose must be adapted to individual tolerability, response and clinical status.
Nato je treba vzdrževalni odmerek prilagoditi toleranci, odzivu in kliničnemu stanju posameznika.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF VASCASE AND ASSOCIATED NAMES (SEE ANNEX I)
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA VASCASE IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
The following sections were harmonised:
Usklajena so bila naslednja poglavja:
This can make it difficult to breathe or swallow.
To lahko povzroči težave z dihanjem ali požiranjem.
- Martindale: The Complete Drug Reference 36.
- Martindale: The Complete Drug Reference 36 (Celotne reference o zdravilih, 36. izdaja).
The following dosage schedules are recommended:
Priporočene so naslednje sheme odmerjanja:
In general, the heart rate remains unchanged.
Srčna frekvenca se na splošno ne spremeni.
The haemodynamic and clinical effects occur promptly and persist.
Hemodinamski in klinični učinki se pojavijo takoj in ostanejo prisotni.
Vascace is not suitable for people with certain types of heart problem.
Zdravilo Vascace ni primerno za osebe z določenimi vrstami težav s srcem.
Domaniewska 39B 02-672 / Warsaw Poland
Domaniewska 39B 02-672 / Warsaw Poljska
Roche Nederland BV Beneluxlaan 2A 3446 GG Woerden Netherlands
Roche Nederland BV Beneluxlaan 2A 3446 GG Woerden Nizozemska
It is effective in all degrees of essential hypertension as well as in renal hypertension.
Učinkovit je pri vseh stopnjah esencialne in tudi renalne hipertenzije.
In some cases, reducing the dose may help.
V nekaterih primerih lahko koristi zmanjšanje odmerka.
(It is also better to avoid Vascace in early pregnancysee the sections on ‘Pregnancy' and ‘Breast-feeding'.)
(Bolje je tudi, če se zdravilu Vascace v zgodnji nosečnosti izogibate - glejte poglavji "Nosečnost" in "Dojenje".)
Maximum plasma concentrations are reached within 2 hours after administration and are directly related to dosage.
Največja koncentracija v plazmi je dosežena v 2 urah po uporabi in je neposredno povezana z odmerkom.
1995;10 (4):221-227) raised the question of whether the once daily dosing schedule in hypertension is sufficient, no further discussion of the results of this study in comparison with the other studies conducted with cilazapril was provided by the MAH.
1995;10 (4):221-227) postavilo vprašanje, ali je shema odmerjanja enkrat dnevno pri hipertenziji zadostna, imetnik dovoljenja za promet z zdravilom ni predložil nadaljnje razprave o rezultatih te študije v primerjavi z drugimi študijami, izvedenimi s cilazaprilom.
A variant form is angioedema of the intestine, which tends to occur within the first 24-48 hours of treatment.
Druga oblika je črevesni angioedem, ki se ponavadi pojavi v prvih 24 do 48 urah po zdravljenju.
Greece, Ireland, United Kingdom: Vascace Italy, Portugal: Inibace
Grčija, Irska, Velika Britanija: Vascace Italija, Portugalska: Inhibace
Roche Austria GmbH, Engelhorngasse 3, A - 1211 Vienna Austria
Roche Austria GmbH, Engelhorngasse 3, A - 1211 Vienna Avstrija
Therefore the CHMP was of the view that digitalis should not necessarily be mentioned because concomitant therapy with digitalis in general use (as a basic therapy) is not recommended today.
CHMP je zato menil, da digitalisa ni nujno treba omeniti, saj sočasno zdravljenje z digitalisom pri splošni uporabi (kot osnovno zdravljenje) danes ni priporočljivo.
Roche S.p.A Via G.B Stucchi 110 20052/Monza Italy
Roche S.p.A Via G.B Stucchi 110 20052/Monza Italija
indometacin and ibuprofen.
(aspirin), indometacin in ibuprofen.
In a careful literature search, covering the time period up to November 2009, only a single publication was identified, describing a case report of a patient with diabetic nephropathy and cirrhotic ascites.
Ob skrbnem pregledu literature do novembra 2009 je bilo mogoče odkriti le eno publikacijo, ki opisuje primer bolnika z diabetično nefropatijo in cirotičnim ascitesom.
Roche Bulgaria EOOD 16, Bvalo pole Str. 1618 / Sofia Bulgaria
Roche Bulgaria EOOD 16, Bvalo pole Str. 1618 / Sofia Bolgarija
- the Summary of Products Characteristic, labelling and package leaflet proposed by the Marketing Authorisation Holders have been assessed based on the documentation submitted and the scientific discussion within the Committee,
- povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo, ki so jih predlagali imetniki dovoljenja za promet z zdravilom, so bili ocenjeni na podlagi predložene dokumentacije in znanstvene razprave znotraj Odbora.
Vascace and associated names (see Annex I) 0.5 mg film-coated tablets Vascace and associated names (see Annex I) 1 mg film-coated tablets Vascace and associated names (see Annex I) 2.5 mg film-coated tablets Vascace and associated names (see Annex I) 5 mg film-coated tablets [See Annex I - To be completed nationally]
Vascace in z njim povezana imena (Glejte Dodatek I) 0,5 mg filmsko obložene tablete Vascace in z njim povezana imena (Glejte Dodatek I) 1 mg filmsko obložene tablete Vascace in z njim povezana imena (Glejte Dodatek I) 2,5 mg filmsko obložene tablete Vascace in z njim povezana imena (Glejte Dodatek I) 5 mg filmsko obložene tablete [Glejte Dodatek I - Izpolni država članica]
Routine monitoring of potassium and creatinine is part of normal medical practice for these patients.
Redne kontrole kalija in kreatinina so del normalne zdravstvene oskrbe teh bolnikov.
Your doctor will then increase your dose until your blood pressure is under control.
Zdravnik vam bo potem odmerek povečeval, dokler krvni tlak ne bo urejen.
This helps to lower your blood pressure.
Tako pomaga znižati krvni tlak.
Although the study by Carlsen et al (Carlsen JE, Buchmann M, Hoeglund C, Pellinen T, Honkanen T, Soerensen OH, et al. 24-hour antihypertensive effect of oral cilazapril?
Čeprav se je na podlagi študije Carlsen et al (Carlsen JE, Buchmann M, Hoeglund C, Pellinen T, Honkanen T, Soerensen OH, et al. 24-hour antihypertensive effect of oral cilazapril?
If possible, diuretic therapy should be discontinued temporarily.
Če je mogoče, je treba zdravljenje z diuretikom začasno prekiniti.